quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:07·108d
INSIDERFiling
VYNE Therapeutics Inc. logo

CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,448 shares, decreasing direct ownership by 2% to 115,239 units (SEC Form 4)

VYNE· VYNE Therapeutics Inc.
Health Care
Original source

Companies

  • VYNE
    VYNE Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jul 31UpdateBTIG Research-
  • Nov 18UpdateBTIG Research$8.00
  • Dec 6UpdateHC Wainwright & Co.$7.00

Related

  • INSIDER21d
    SEC Form 4 filed by Zeronda Tyler
  • INSIDER21d
    SEC Form 4 filed by Stuart Iain
  • INSIDER21d
    SEC Form 4 filed by Harsch Mutya
  • INSIDER21d
    SEC Form 4 filed by Domzalski David
  • SEC23d
    SEC Form S-4 filed by VYNE Therapeutics Inc.
  • SEC43d
    SEC Form 8-K filed by VYNE Therapeutics Inc.
  • SEC55d
    SEC Form 10-K filed by VYNE Therapeutics Inc.
  • SEC83d
    SEC Form 425 filed by VYNE Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022